Best Practices in the Management of Relapsing
Multiple Sclerosis: Advanced Strategies
for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 20, 2018 to April 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals, Biogen, and Celgene

Description:
Multiple Sclerosis (MS) is a chronic, progressive disease and is the most common neurological cause of disability among young adults. In many cases, MS may not be diagnosed for months to years after the onset of symptoms and current treatment is focused on disease-modifying agents to help lessen the frequency and severity of relapses, reduce lesions in the brain, and aid in slowing or stopping disability. With screening and diagnosing, it is critical that physicians note a detailed patient history and perform a complete physical and neurological exam. In addition, strategies for diagnosis include an MRI, evoked potentials (EP) and a spinal fluid analysis. Several factors must be considered when selecting a treatment regimen including variations in clinical and MRI evidence of disease. Thankfully many advances in diagnosis and treatment have arrived in recent years, allowing patients to better manage their symptoms, improve their quality of life, and increase mortality. The numerous revisions and advances in diagnostic criteria and multiple, new emerging therapies have shown new agents have the ability to improve outcomes in both safety and efficacy. Clinicians need to compare these new options with current therapies to form an individualized treatment strategy for each patient as symptoms are highly variable from person to person.

Upon Completion of this activity, participants will be able to:

  • Examine the mechanisms of action, efficacy, and safety profiles of current and emerging relapsing multiple sclerosis (MS) therapies and their effect on staging and sequencing

  • Analyze newly available therapies for patients with relapsing MS that have had inadequate response to two or more previous therapies

  • Review patient, disease, and treatment characteristics that factor into relapsing MS treatment selection and strategies for identifying when to switch therapies

  • Explore recent guideline updates on the role of MRI in evaluating prognosis, disease progression and therapeutic decision-making for improved relapsing MS patient outcomes

  • Evaluate quality standards, health care policy, and benefit designs to enhance clinical and economic outcomes for patients with MS

  • Review the role of autoinjectors in the management of relapsing MS and discuss which patients could benefit from their use
     

Faculty: George Hutton, MD
Medical Director
Maxine Mesinger MS Comprehensive Care Center
Baylor College of Medicine
McNair Campus

Disclosure:

Dr. Hutton serves on an advisory board for Genzyme and Novartis. He also receives research support from Biogen, Genzyme, Hoffman-LaRoche, and MedImmune. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals, Biogen, and Celgene

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue